Early cancer diagnosis, prognosis and monitoring
Each year, cancer caused about 13% (8 million) of all human deaths worldwide and this rate is increasing as people live older and lifestyle changes in the developing world. In addition to its impact on patients, the disease represents a major economic burden for health systems. Overall direct and indirect costs of cancer in 2007 were estimated to be $227 billion, just for the United-States.
If the chances of surviving the cancer vary greatly with its type and location, it also greatly vary with the extent of disease at the start of treatment. Moreover, the later the cancer is diagnosed, the most extensive and costly will be the treatment.
Despite all those facts, few multiplexed molecular based diagnostics exist for both cancer diagnosis and prognosis.
Cancer diagnosis may be based on certain biomarkers in the blood, which individually are not very accurate but, when combined, can be quite suitable. Multiplexed tests here take full dimension allowing detection in a single test of a wide set of parameters.
AXO Science goal is to improve the detection of cancerous tumors, especially at an early stage where they can be treated by surgery, but also to classify cases (stratification) to allow clinicians to precisely adapt treatment and ultimately reduce mortality while reducing treatment costs. This solution will both answer to laboratories need to provide diagnostic tests as well as hospitals need for a therapy monitoring “companion” test once the disease is diagnosed.
For its cancer diagnosis research, AXO Science obtained €530K from the European Union within an FP7 project currently underway.